Showing results (211-220 of 260) with videos related to

Sort By:
Pageof 26
Oncogene|September 21, 2021
Increased BUB1B/BUBR1 expression contributes to aberrant DNA repair activity leading to resistance to DNA-damaging agentsKazumasa Komura, Teruo Inamoto, Takuya Tsujino, et al.
Urologic Oncology|March 29, 2022
Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinomaTaizo Uchimoto, Ko Nakamura, Kazumasa Komura, et al.
Cancer Immunology, Immunotherapy : CII|February 25, 2026
A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortiumTakafumi Yanagisawa, Keiichiro Mori, Tatsushi Kawada, et al.
In Vivo (Athens, Greece)|January 2, 2023
Tissue Distribution of Cisplatin by Intra-arterial Infusion Route in Comparison to Systemic Route: Implication to Therapy for Node-positive Bladder CancerAtsushi Ichihashi, Teruo Inamoto, Taizo Uchimoto, et al.
World Journal of Urology|September 17, 2014
Add-on anticholinergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving α1-blocker treatment: a multi-centre, prospective, randomised studyOsamu Yokoyama, Akira Tsujimura, Hironobu Akino, et al.
BJU International|July 24, 2020
Risk stratification for the prediction of overall survival could assist treatment decision-making at diagnosis of castration-resistant prostate cancer: a multicentre collaborative study in JapanTaizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, et al.
Medical Oncology (Northwood, London, England)|November 23, 2019
Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancerTaizo Uchimoto, Kazumasa Komura, Yuya Fujiwara, et al.
Japanese Journal of Clinical Oncology|May 17, 2026
Development of a prognostic model for elderly patients with metastatic clear cell renal cell carcinoma treated with first-line immuno-oncology combination therapyShinya Watanabe, Yuto Matsushita, Yuya Oishi, et al.
European Urology Open Science|July 11, 2022
Site-specific Risk Stratification Models for Postoperative Recurrence and Survival Prediction in Patients with Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy: Better Stratification for Adjuvant TherapyMakito Miyake, Kota Iida, Nobutaka Nishimura, et al.
Nature Communications|January 17, 2023
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancerTakuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, et al.
Pageof 26